Gene targeting in adult organs using in vivo cleavable donor plasmids for CRISPR-Cas9 and CRISPR-Cas12a

被引:2
|
作者
Ishibashi, Riki [1 ,2 ]
Maki, Ritsuko [1 ]
Toyoshima, Fumiko [1 ,2 ,3 ]
机构
[1] Kyoto Univ, Inst Life & Med Sci, Dept Biosyst Sci, Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Biostudies, Dept Mammalian Regulatory Networks, Sakyo Ku, Kyoto 6068502, Japan
[3] Tokyo Med & Dent Univ TMDU, Med Res Inst, Dept Homeostat Med, Bunkyo Ku, Yushima, Tokyo 1138510, Japan
基金
日本学术振兴会;
关键词
HYDRODYNAMIC INJECTION; RNA INTERFERENCE; HIGH-LEVEL; NAKED DNA; EXPRESSION; GENOME; DELIVERY; HEPATOCYTES; LIVER; CPF1;
D O I
10.1038/s41598-024-57551-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The CRISPR-Cas system for in vivo genome editing is a powerful tool for gene therapy against several diseases. We have previously developed the pCriMGET_9-12a system, an in vivo cleavable donor plasmid for precise targeted knock-in of exogenous DNA by both Cas9 and Cas12a. Here, we show that the pCriMGET_9-12a system can be applied for in vivo in-frame knock-in of exogenous DNA in adult mouse liver by hydrodynamic delivery of the targeting plasmids. The in vivo cleavable pCriMGET_9-12a donor plasmids significantly increased the knock-in efficiency of both CRISPR-Cas9 and CRISPR-Cas12a in the adult mouse liver compared to uncleavable donor plasmids. This strategy also achieved in-frame reporter gene knock-in without indel mutations. Therefore, in vivo gene targeting using the pCriMGET_9-12a system may contribute to the establishment of safer, more precise, versatile and efficient gene therapy methods in adult organs.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Gene targeting in adult organs using in vivo cleavable donor plasmids for CRISPR-Cas9 and CRISPR-Cas12a
    Riki Ishibashi
    Ritsuko Maki
    Fumiko Toyoshima
    Scientific Reports, 14
  • [2] Development of an in vivo cleavable donor plasmid for targeted transgene integration by CRISPR-Cas9 and CRISPR-Cas12a
    Riki Ishibashi
    Ritsuko Maki
    Satsuki Kitano
    Hitoshi Miyachi
    Fumiko Toyoshima
    Scientific Reports, 12
  • [3] Development of an in vivo cleavable donor plasmid for targeted transgene integration by CRISPR-Cas9 and CRISPR-Cas12a
    Ishibashi, Riki
    Maki, Ritsuko
    Kitano, Satsuki
    Miyachi, Hitoshi
    Toyoshima, Fumiko
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Multiplexed CRISPR-Cas9 and CRISPR-Cas12a Systems for Genome Editing in Plants
    Li, Gen
    Qi, Yiping
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2023, 59 : S67 - S67
  • [5] 基因编辑工具CRISPR-Cas9与CRISPR-Cas12a的比较与应用
    王炀坤
    纪世新
    苏莹莹
    孙英旗
    宋相伟
    长春师范大学学报, 2023, 42 (12) : 107 - 112
  • [6] In vivo gene therapy potentials of CRISPR-Cas9
    Xue, H-Y
    Zhang, X.
    Wang, Y.
    Xiaojie, L.
    Dai, W-J
    Xu, Y.
    GENE THERAPY, 2016, 23 (07) : 557 - 559
  • [7] In vivo gene therapy potentials of CRISPR-Cas9
    H-Y Xue
    X Zhang
    Y Wang
    L Xiaojie
    W-J Dai
    Y Xu
    Gene Therapy, 2016, 23 : 557 - 559
  • [8] In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9
    He, Zhi-Yao
    Zhang, Ya-Guang
    Yang, Yu-Han
    Ma, Cui-Cui
    Wang, Ping
    Du, Wei
    Li, Ling
    Xiang, Rong
    Song, Xiang-Rong
    Zhao, Xia
    Yao, Shao-Hua
    Wei, Yu-Quan
    HUMAN GENE THERAPY, 2018, 29 (02) : 223 - 233
  • [9] In Vivo Delivery of Large Plasmids and CRISPR-Cas9 to Edit GFP Gene Using Dendrimer Nanoparticles
    Srinageshwar, B.
    Florendo, M. N.
    Munro, N. M.
    Macdonald, B. S.
    Dehart, L.
    Peruzzaro, S.
    Koneru, S.
    Baiyasi, S.
    Antcliff, A.
    Andrews, M. M. M.
    Swanson, D.
    Dunbar, G. L.
    Bakke, J. L.
    Sharma, A. A.
    Rossignol, J.
    CELL TRANSPLANTATION, 2019, 28 (04) : 485 - 486
  • [10] CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
    Rim, John Hoon
    Gopalappa, Ramu
    Gee, Heon Yung
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (18): : 1722 - 1722